Stock's Thoracic Outlet Syndrome Forces Mets Out of Playoff Push Without Starting Depth

Robert Stock's comeback bid ended Wednesday when the Mets placed the 36-year-old right-hander on the 15-day injured list due to finger numbness stemming from March thoracic outlet syndrome surgery. Stock, who had been slated to start against Baltimore, confirmed the condition worsens predictably—onset typically occurs around 60-70 pitches—making him unreliable as a bulk innings option. The timing is brutal: New York also lost reliever Daniel Duarte (hamstring) to the IL on the same day, stripping away depth from a bullpen already taxed after absorbing 8⅔ innings across the previous two games.

Stock's injury is not a surprise setback but a structural collapse. His 5.93 ERA across seven starts this season masked the real problem: a pitcher whose body cannot sustain a major-league workload. His first win since 2019 felt like vindication—a journeyman who had pitched in Korea and for the independent Long Island Ducks finally getting a second act. But that narrative crumbled the moment his neurological system betrayed him. At 36, with a surgically repaired thoracic outlet, Stock was always a high-variance play. The Mets gambled on his ability to give them league-average innings down the stretch. They lost that bet.

Duarte's loss adds a second layer of urgency. The 29-year-old compiled a 2.12 ERA with 30 strikeouts in 29⅔ innings, functioning as a credible middle-relief option with occasional closing duties (two saves). A 2-0 record in 24 appearances suggests modest leverage usage, but his strikeout rate (9.05 per nine) and control (2.11 BB/9) placed him among the Mets' most reliable bullpen arms. Losing him in mid-September, when teams are building for a playoff push or accepting a collapse, removes a weapon the organization cannot easily replace from the available talent pool.

From a betting lens, the Mets' pitching flexibility has narrowed significantly. Without Stock and with Duarte sidelined, New York is committing to shorter outings from remaining starters and deeper bullpen usage in games where margin of victory is thin. This structurally favors unders on Mets team totals and overs on their opponent totals in the remaining games—not because the Mets offense has suddenly weakened, but because games featuring extended bullpen play tend to accumulate runs at a lower rate than those with routine six-plus-inning starts. The bullpen quality drop is real: replacing Stock's rotation spot with Xzavion Curry from Triple-A is a sideways-to-downward move in stuff and experience. Additionally, Jefry Yan (recalled to replace Duarte) lacks the proven track record Duarte established. Over the final 15 games of the season, expect the Mets' run prevention to lag their preseason projection, and books will be slow to adjust that gap into September numbers.

Stock's parting comment—that next year, he hopes to be part of the conversation for a roster spot—should be parsed carefully. At 36, with a chronic condition that emerges at a predictable pitch threshold, Stock is unlikely to solve his problem through rest alone. The Mets' investment in his rehabilitation has yielded neither durability nor performance. That outcome ripples into their bullpen composition heading into the offseason and signals to other teams that the cost of reclaiming aging arms with previous injury history remains prohibitively high.